Literature DB >> 16525588

The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.

David Jiménez1, Gema Díaz, Elena Marín, Rafael Vidal, Antonio Sueiro, Roger D Yusen.   

Abstract

Patients with a first episode of symptomatic pulmonary embolism (PE) have a higher risk of recurrent venous thromboembolism (VTE) than patients with a first episode of proximal lower extremity deep vein thrombosis (DVT). Patients with symptomatic DVT and silent PE may have a different risk of VTE recurrence than patients that have symptomatic DVT without PE. Therefore, it was the aim of this prospective cohort study to compare the risk of recurrent symptomatic VTE in patients with proximal lower extremity DVT and silent PE to the risk in patients that only have proximal lower extremity DVT. Ninety-one consecutive outpatients presenting to the emergency department of a university hospital subsequently hospitalised with a first episode of unprovoked symptomatic proximal lower extremity DVT, and without new pulmonary symptoms were included. Standard initial treatment consisted of intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin for 5-7 days, overlapped with oral vitamin-K antagonist therapy, with long-term oral vitamin-K antagonist therapy (goal INR 2.5 [2.0-3.0]). Study endpoints were: symptomatic recurrent DVT, new PE, and recurrent PE, evaluated by standard objective testing. At enrollment, 28 of 91 (31%) patients with DVT had silent PE. In the patients with DVT and silent PE, there were 3 VTE recurrences during 20 person-years of follow-up, while there were no VTE recurrences during 61 person-years of follow- up in the patients with isolated DVT. The Kaplan-Meier estimated VTE recurrence rate at 1 year after the diagnosis of DVT was 11% (95% CI: 2-28%) for patients with symptomatic DVT and silent PE, compared to 0% in patients with isolated symptomatic DVT (p=0.0045). In patients with a first episode of unprovoked symptomatic acute proximal lower extremity DVT, the risk of recurrent VTE was significantly higher in those with silent PE compared to those without PE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525588     DOI: 10.1160/TH05-10-0677

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

2.  Decrease in shunt volume in patients with cryptogenic stroke and patent foramen ovale.

Authors:  Christian Tanislav; Manfred Kaps; Marek Jauss; Erwin Stolz; Wolfgang Pabst; Max Nedelmann; Mathias Grebe; Frank Reichenberger; Jens Allendoerfer
Journal:  BMC Neurol       Date:  2010-12-29       Impact factor: 2.474

Review 3.  Epidemiology of recurrent venous thrombosis.

Authors:  D D Ribeiro; W M Lijfering; S M Barreto; F R Rosendaal; S M Rezende
Journal:  Braz J Med Biol Res       Date:  2011-12-23       Impact factor: 2.590

Review 4.  The epidemiology of venous thromboembolism.

Authors:  John A Heit; Frederick A Spencer; Richard H White
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

5.  Silent Pulmonary Embolism in Deep Vein Thrombosis: Relationship and Risk Factors.

Authors:  Yadong Shi; Tao Wang; Yuan Yuan; Haobo Su; Liang Chen; Hao Huang; Zhaoxuan Lu; Jianping Gu
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

6.  Is routine screening for silent pulmonary embolism justified in patients with deep vein thrombosis?

Authors:  Marcela Juliano Silva; Cynthia de Almeida Mendes; Sergio Kuzniec; Mariana Krutman; Nelson Wolosker
Journal:  J Vasc Bras       Date:  2021-06-25

7.  Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Giuseppe M Andreozzi; Angelo A Bignamini; Giovanni Davì; Gualtiero Palareti; Jiří Matuška; Martin Holý; Katarzyna Pawlaczyk-Gabriel; Andrej Džupina; German Y Sokurenko; Yury P Didenko; Laurentia D Andrei; Gianfranco Lessiani; Adriana Visonà
Journal:  Circulation       Date:  2015-09-25       Impact factor: 29.690

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.